Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent Itk/Jak3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
aclaris therapeutics宣佈在Phase 2a臨床試驗中首例患者接受了ATI-2138，一個用於治療中度至重度特應性皮炎的調查性口服共價ITK/JAK3抑制劑。
